Actively Recruiting
Zanubrutinib in Combination With Obinutuzumab (ZO) for Newly Diagnosed Follicular Lymphoma
Led by The First Affiliated Hospital of Xiamen University · Updated on 2024-09-03
39
Participants Needed
1
Research Sites
178 weeks
Total Duration
On this page
Sponsors
T
The First Affiliated Hospital of Xiamen University
Lead Sponsor
S
Shanxi Province Cancer Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
To evaluate the efficacy and side effects of Zanubrutinib combined with Obinutuzumab (ZO) in the treatment of newly diagnosed follicular lymphoma.
CONDITIONS
Official Title
Zanubrutinib in Combination With Obinutuzumab (ZO) for Newly Diagnosed Follicular Lymphoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Diagnosed with follicular lymphoma stage II-IV requiring treatment according to GELF criteria
- ECOG performance status score between 0 and 2
- At least one measurable or evaluable lymphoma lesion based on Lugano 2014 criteria
- Negative HBV-DNA test if HBV-positive serology
- Normal liver and kidney function unless related to lymphoma
- Signed informed consent to participate in the study
You will not qualify if you...
- Presence of medically significant CNS lymphoma, molluscum contagiosum, or large cell transformation
- HIV-positive or active HCV infection confirmed by RNA test
- Active or uncontrolled autoimmune hemolytic anemia or immune thrombocytopenia
- Transfusion-dependent thrombocytopenia or bleeding disorders
- Known bleeding disorders requiring treatment with potent cytochrome P450 3A inhibitors
- Acute coronary syndrome, stroke, or intracranial hemorrhage within 6 months prior to enrollment
- Major surgery within 28 days or minor surgery within 7 days prior to enrollment
- Severe chronic obstructive pulmonary disease with hypoxemia
- Active bacterial, fungal, or viral infections not controlled by systemic therapy
- Other malignant tumors within the last 2 years except certain early-stage cancers
- Pregnancy or breastfeeding; females must have a negative pregnancy test and use contraception during and for 12 weeks after treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Bing Xu
Xiamen, Fujian, China, 361003
Actively Recruiting
Research Team
B
Bing Xu, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here